|
January 12, 2006 Categories: Uncategorized Posted by admin
Daiichi Sankyo has signed a deal worth up to $340 million with KAI Pharmaceuticals for the global development and commercialization of KAI-9803, an experimental treatment for the prevention of myocardial tissue death. While this could represent an astute move by Daiichi to boost its cardio business, it could also be seen as a desperate pipeline-filling attempt following CS-505’s recent failure.
Full news
|
|
